Literature DB >> 29157380

Staging of Non-Small-Cell Lung Cancer.

Tim Akhurst1.   

Abstract

Staging of lung cancer serves 2 purposes; it attempts to classify patients into groups where particular treatments are appropriate and defines those groups based on expected prognosis. The eighth edition of the International Association for the Study of Lung Cancer staging system deals with the issues raised by screening with fine cut computed tomography. Each phase of staging is a legitimate dataset on its own. Molecular profiling of lung cancer has led to the development of an increasing number of novel agents to treat systemic disease. Prognosis is increasingly determined by genetic susceptibility of the specific cancer.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  EBUS; FDG PET CT; Non–small-cell lung cancer; Staging; TNM

Mesh:

Year:  2017        PMID: 29157380     DOI: 10.1016/j.cpet.2017.09.004

Source DB:  PubMed          Journal:  PET Clin        ISSN: 1556-8598


  19 in total

1.  Diagnostic and prognostic value of CT perfusion parameters in patients with advanced NSCLC after chemotherapy.

Authors:  Guangyao Lin; Yuan Sui; Yiming Li; Wenqi Huang
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

2.  Positron emission tomography/computed tomography and endobronchial ultrasound-guided transbronchial needle aspiration to evaluate the status of N2 in preoperative non-small cell lung cancer: a diagnostic test.

Authors:  Shiwei Nie; Wencheng Yu; Xilin Hu; Hanlin Xu; Ruran Wen; Wenjie Jiao; Kaihua Tian
Journal:  J Thorac Dis       Date:  2022-06       Impact factor: 3.005

3.  MicroRNA-891a-5p is a novel biomarker for non-small cell lung cancer and targets HOXA5 to regulate tumor cell biological function.

Authors:  Nianqing Wan; Jianxiao Zheng
Journal:  Oncol Lett       Date:  2021-05-02       Impact factor: 2.967

Review 4.  Consistency of recommendations for the diagnosis and treatment of non-small cell lung cancer: a systematic review.

Authors:  Zhe Zhang; Sen Yang; Yanfang Ma; Hanqiong Zhou; Xuan Wu; Jing Han; Jiabao Hou; Lidan Hao; Jonathan D Spicer; Young Wha Koh; Mariano Provencio; Noemi Reguart; Tetsuya Mitsudomi; Qiming Wang
Journal:  Transl Lung Cancer Res       Date:  2021-06

5.  Genetic variants of CHEK1, PRIM2 and CDK6 in the mitotic phase-related pathway are associated with nonsmall cell lung cancer survival.

Authors:  Rui Mu; Hongliang Liu; Sheng Luo; Edward F Patz; Carolyn Glass; Li Su; Mulong Du; David C Christiani; Lei Jin; Qingyi Wei
Journal:  Int J Cancer       Date:  2021-06-10       Impact factor: 7.396

6.  Overexpression of miR-518b in non-small cell lung cancer serves as a biomarker and facilitates tumor cell proliferation, migration and invasion.

Authors:  Xinfang Zhang; Ying Hu; Cuixue Gong; Chunjie Zhang
Journal:  Oncol Lett       Date:  2020-05-22       Impact factor: 2.967

7.  MicroRNA-1298 is downregulated in non-small cell lung cancer and suppresses tumor progression in tumor cells.

Authors:  Zhonghai Du; Jun Wu; Juan Wang; Yan Liang; Sensen Zhang; Zhimei Shang; Wenchao Zuo
Journal:  Diagn Pathol       Date:  2019-12-04       Impact factor: 2.644

8.  The role of long intergenic non-coding RNA for kinase activation (LINK-A) as an oncogene in non-small cell lung carcinoma.

Authors:  Parichehr Maleki; Seyed Javad Mowla; Mohammad Taheri; Soudeh Ghafouri-Fard; Jamshid Raheb
Journal:  Sci Rep       Date:  2021-02-18       Impact factor: 4.379

9.  Cediranib Induces Apoptosis, G1 Phase Cell Cycle Arrest, and Autophagy in Non-Small-Cell Lung Cancer Cell A549 In Vitro.

Authors:  Menghuan Guo; Zhiyuan Liu; Jing Si; Jinhua Zhang; Jin Zhao; Zhong Guo; Yi Xie; Hong Zhang; Lu Gan
Journal:  Biomed Res Int       Date:  2021-03-29       Impact factor: 3.411

10.  Upregulated miR-665 expression independently predicts poor prognosis of lung cancer and facilitates tumor cell proliferation, migration and invasion.

Authors:  Jinbing Xia; Dengping Li; Xiaoliang Zhu; Wenying Xia; Zhenyong Qi; Guanhua Li; Qian Xu
Journal:  Oncol Lett       Date:  2020-03-11       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.